Results 161 to 170 of about 3,952,882 (246)

Assessment of bone health and bone mineral density in patients with mucopolysaccharidosis receiving enzyme replacement therapy. [PDF]

BMC Pediatr
El Feil NSA, Abuzaid Y, Mobarak A.
europepmc   +1 more source

Mitochondria and Neuromast Tagging With Fluorescent Gallium‐Triapine Analogues: In Cellulo MP FLIM and Zebrafish Live Imaging

Advanced Science, EarlyView.
Fluorescent BODIPY‐conjugated thiosemicarbazone ligands and their Ga(III), In(III), and Fe(III) complexes, inspired by Triapine, are developed as theranostic agents. Multiphoton FLIM and confocal microscopy in cancer cells and zebrafish reveal real‐time uptake, mitochondrial localisation, and whilst spectroscopic assays indicated preserved complex ...
Megan J. Green, Michael W. Jones, Merissa Saleem, Haobo Ge, Melita Tvardauskaite, Julia Dudzic, Fernando Cortezon‐Tamarit, Rory L. Arrowsmith, Charareh Pourzand, Gabriele Kociock‐Kohn, Nicholas H. Rees, Jonathan R. Dilworth, Stephen Faulkner, Stanley W. Botchway, David Gurevich, Sofia I. Pascu   +15 more
wiley   +1 more source

AAV9-mediated GAA gene therapy following enzyme replacement therapy discontinuation in children with infantile-onset Pompe disease. [PDF]

EClinicalMedicine
Liu X, Mao Y, Hu L, He W, Wang X, Guo X, Li M, Wang Y, Wang Y, Ma W, Yuan Y, Wang Z, Yu S, Zhang S, Wu S, Dong X, Wu X, Yang G.   +17 more
europepmc   +1 more source

Combating Inflammation and Promoting Anabolism in Osteoarthritic Cartilage Defect With an MMP13‐Sensing Dual‐Drug Scaffold

Advanced Science, EarlyView.
ABSTRACT Osteoarthritis (OA) is a widespread degenerative joint condition marked by progressive cartilage breakdown, and a chronic inflammatory microenvironment, where conventional therapies largely fail to halt disease progression. To address this unmet need, an intra‐articularly implantable, disease‐responsive scaffold was developed for combinatorial
Zhen Zhang, Bangheng Liu, Yulei Mu, Huiqun Zhou, Liang Ma, Chenjie Xu, Dong‐An Wang   +6 more
wiley   +1 more source

From diagnosis to disease-specific treatment: first experience with enzyme replacement therapy for Fabry disease in North Macedonia-a case series. [PDF]

Front Med (Lausanne)
Karanfilovski V, Nikolov IG, Dzekova Vidimliski P, Balkanov SK, Severova G, Stojanoska A, Gjorgjievski N.   +6 more
europepmc   +1 more source

Enzyme replacement therapy and antibodies in late-onset Pompe disease

Molecular Genetics and Metabolism Reports, 2014
I. Schneider, M. Deschauer, F. Hanisch
doaj   +1 more source

A Review on Catalytic Nanostructured Electrodes for Wearable and Implantable Abiotic Glucose Fuel Cells

Advanced Science, EarlyView.
This review identifies current and future directions in abiotic nanostructured catalysts to develop reliable and sustainable glucose fuel cells to power the next generation of bioelectronic devices. ABSTRACT The global rise in incidence of chronic diseases has led to the demand for innovative solutions that help patients manage their conditions with ...
Asghar Niyazi, Hannah S. Leese, Benjamin Metcalfe, Mirella Di Lorenzo   +3 more
wiley   +1 more source

Two Faces of the Right Ventricle in Fabry Cardiomyopathy: Septal-Coupled and Atrial-Coupled Strain Patterns and Their Differential Associations with Enzyme Replacement Therapy. [PDF]

Biomolecules
Sung KT, Niu DM, Hsu SF, Liu ME, Lin PL, Lai YH, Yang HW, Lu YH, Tsai CT, Hung TC, Chen PS, Hung CL.   +11 more
europepmc   +1 more source

An Adipocyte MKK3–p38β Axis Preserves Insulin Responsiveness in Mice and Is Reciprocally Altered in Human Obesity

Advanced Science, EarlyView.
The adipocyte MKK3–p38β axis emerges as an adaptive stress‐response pathway during obesity. Human visceral adipose tissue analyses, adipocyte‐specific mouse models, and primary adipocytes show that the MKK3–p38β axis supports insulin responsiveness by restraining p70S6K‐dependent inhibitory IRS1 feedback and preserving AKT–GLUT4 signaling. This pathway
Edgar Bernardo, Nuria Matesanz, Jorge‐Luis Torres, Alba C. Arcones, Juan Ignacio Jiménez‐Loygorri, Alfonso Mora, Leticia Herrera‐Melle, Luis Leiva‐Vega, Maria Elena Rodriguez, Lourdes Hernández‐Cosido, Marta Leon, Paula Yong González, Teresa Durán, Tamara Parracho, Francisca Mulero, Rubén Nogueiras, J. Simon C. Arthur, Angel R. Nebreda, Roger J. Davis, Miguel Marcos, Guadalupe Sabio   +20 more
wiley   +1 more source

Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease. [PDF]

Orphanet J Rare Dis
Lerario A, Abati E, Sciacco M, Comi GP, Desantis V, D'Amore S, Solimando AG, Ria R, Corti S, Spataro F.   +9 more
europepmc   +1 more source